"Metronidazole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS. It has also been proposed as a radiation sensitizer for hypoxic cells. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985, p133), this substance may reasonably be anticipated to be a carcinogen (Merck, 11th ed).
| Descriptor ID |
D008795
|
| MeSH Number(s) |
D02.640.672.500 D03.383.129.308.658.500
|
| Concept/Terms |
Metronidazole- Metronidazole
- 2-Methyl-5-nitroimidazole-1-ethanol
- 2 Methyl 5 nitroimidazole 1 ethanol
Metronidazole Hydrochloride- Metronidazole Hydrochloride
- Hydrochloride, Metronidazole
- Metronidazole Monohydrochloride
- Monohydrochloride, Metronidazole
Metronidazole Phosphate- Metronidazole Phosphate
- Phosphate, Metronidazole
- Metronidazole Phosphoester
- Phosphoester, Metronidazole
|
Below are MeSH descriptors whose meaning is more general than "Metronidazole".
Below are MeSH descriptors whose meaning is more specific than "Metronidazole".
This graph shows the total number of publications written about "Metronidazole" by people in this website by year, and whether "Metronidazole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 3 | 4 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 2 | 3 |
| 2000 | 6 | 4 | 10 |
| 2001 | 4 | 2 | 6 |
| 2002 | 0 | 2 | 2 |
| 2003 | 2 | 2 | 4 |
| 2004 | 1 | 2 | 3 |
| 2005 | 3 | 3 | 6 |
| 2006 | 2 | 3 | 5 |
| 2007 | 3 | 1 | 4 |
| 2008 | 0 | 3 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 3 | 4 | 7 |
| 2012 | 1 | 2 | 3 |
| 2013 | 3 | 3 | 6 |
| 2014 | 0 | 3 | 3 |
| 2015 | 3 | 2 | 5 |
| 2016 | 1 | 6 | 7 |
| 2017 | 0 | 4 | 4 |
| 2018 | 1 | 3 | 4 |
| 2019 | 4 | 1 | 5 |
| 2020 | 2 | 3 | 5 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metronidazole" by people in Profiles.
-
Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Sci Rep. 2024 04 18; 14(1):8986.
-
Metronidazole and cefazolin vs cefazolin alone for surgical site infection prophylaxis in gynecologic surgery at a comprehensive cancer center. Am J Obstet Gynecol. 2024 Sep; 231(3):326.e1-326.e13.
-
Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother. 2024 Mar 06; 68(3):e0162123.
-
Cut-off value of clarithromycin resistance in the treatment of Helicobacter pylori infection: how low is low? Gut. 2024 01 05; 73(2):374-375.
-
Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One. 2023; 18(11):e0294403.
-
Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024 Jan; 9(1):56-67.
-
Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile. Nat Commun. 2023 07 12; 14(1):4130.
-
Persistent Bacterial Vaginosis and Risk for Spontaneous Preterm Birth. Am J Perinatol. 2024 05; 41(S 01):e2081-e2088.
-
Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol. 2023 02 01; 118(2):269-275.
-
Reduction in Rates of Symptomatic Urinary Tract Infection After Pelvic Reconstructive Surgery: A Quality Improvement Analysis. Urogynecology (Phila). 2022 11 01; 28(11):763-769.